10-Q
Quarterly Report
DAY ONE BIOPHARMACEUTICALS, INC.
DAWN
NASDAQ
CIK: 1845337
File #: 001-40431
Balance Sheet
35 line items · 2 periods
XBRL
| Item | Jun 30, 2024 | Dec 31, 2023 |
|---|---|---|
Assets | ||
Current assets: | ||
Cash and cash equivalents | 239,616,000 | 230,784,000 |
Money market funds | 8,658,000 | 47,003,000 |
U.S. government agency securities | 59,607,000 | 63,202,000 |
Cash equivalents | 164,028,000 | 220,850,000 |
U.S. treasury securities | 95,763,000 | 110,645,000 |
Short-term investments | 122,250,000 | 135,563,000 |
Accounts receivable, net | 9,136,000 | 0 |
Inventory | 151,000 | 0 |
Prepaid expenses and other current assets | 12,005,000 | 8,927,000 |
Total current assets | 383,158,000 | 375,274,000 |
Property and equipment, net | 196,000 | 208,000 |
Operating lease right-of-use asset | 164,000 | 352,000 |
Intangible assets, net | 16,802,000 | 0 |
Deposits and other long-term assets | 117,000 | 214,000 |
Total assets | 400,437,000 | 376,048,000 |
Liabilities and stockholders' equity | ||
Current Liabilities: | ||
Accounts payable | 6,444,000 | 2,576,000 |
Accrued expenses and other current liabilities | 87,072,000 | 26,524,000 |
Current portion of operating lease liability | 190,000 | 408,000 |
Total current liabilities | 93,706,000 | 29,508,000 |
Total liabilities | 93,706,000 | 29,508,000 |
Stockholders' equity | ||
Common stock, $0.0001 par value; 500,000,000 shares authorized as of June 30, 2024 and December 31, 2023; 87,692,916 and 87,227,132 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively | 9,000 | 9,000 |
Additional paid-in-capital | 832,148,000 | 805,107,000 |
Accumulated other comprehensive (loss) income | (22,000) | 9,000 |
Accumulated deficit | (525,404,000) | (458,585,000) |
Total stockholders' equity | 306,731,000 | 346,540,000 |
Additional Paid-in Capital | 832,148,000 | 805,107,000 |
Accumulated Other Comprehensive Income (Loss) | (22,000) | 9,000 |
Accumulated Deficit | (525,404,000) | (458,585,000) |
Common Shares | 9,000 | 9,000 |
Total liabilities and stockholders' equity | 400,437,000 | 376,048,000 |